Investigating how a genetic variant affects survival during pneumococcal sepsis
Official title: Novel coenzyme Q6 variant reveals non-immune determinants of survival during pneumococcal sepsis
Funded at Washington University · NIH-10945803 · Data updated 2026-11-12
This study is looking at how a certain gene might affect how well people with pneumococcal sepsis survive, using a special mouse model to understand the immune system's role, with the hope of finding better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 26, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $739,362 |
| NIH project number | 1R01HL177453-01 |
| Project ID | NIH-10945803 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced pneumococcal sepsis or are at high risk for developing this condition.
✕Less likely to help
Patients who do not have a history of pneumococcal infections or sepsis may not benefit from this research.
What this research studies
This research explores the role of a specific genetic variant in coenzyme Q6 that may influence survival rates in patients suffering from pneumococcal sepsis. The study utilizes a novel mouse model to differentiate between immune and non-immune factors affecting mortality during sepsis. By analyzing how this genetic variant impacts the body's response to infection, the research aims to uncover new insights that could lead to improved treatment strategies for sepsis patients.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that enhance survival rates for patients with pneumococcal sepsis.
How similar studies have gone: While the immune-centric model of sepsis has been widely studied, this research introduces a novel perspective by focusing on non-immune factors, making it a potentially groundbreaking approach.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Morley, Sharon Celeste — Washington University
- Study coordinator: Morley, Sharon Celeste
Related research
Other NIH-funded projects on the same topics.
-
Role of blood flow mechanics and transfusion in sepsis-related tiny-cl vessel clots
A patient-focused look at how red blood cell flow and transfusions might influence tiny blood vessel clots and organ problems in sepsis.
-
STeroids and enhanced Antibiotics for sepsis in Africa with HIV/TB (STARS)
This grant tests whether adding steroids and stronger antibiotics helps adults with severe sepsis tied to HIV/TB in areas with high TB rates.
-
Steroids and better antibiotics for sepsis in people with AIDS in Africa
This study tests whether adding hydrocortisone and stronger antibiotics can improve survival for adults with sepsis who also have AIDS or advanced immune suppression in regions with high TB.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Role of MMP3 in heart dysfunction during sepsis
This research tests whether blocking MMP3 can protect the heart and improve survival during sepsis in adults.
-
Sepsis patient care guided by Ugandan-wide immune profiling
A large NIH-funded study will map how the immune system behaves during sepsis in people in Uganda to improve personalized care for sepsis patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.